Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04566432
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Sponsor: Geneplus-Beijing Co. Ltd.
View on ClinicalTrials.gov
Summary
To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.
Official title: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICIs) or Targeted Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
250
Start Date
2020-07-01
Completion Date
2025-06-30
Last Updated
2024-07-18
Healthy Volunteers
No
Interventions
OTHER
Observation
observe the association of ctDNA with efficacy of treatment
Locations (1)
Shanghai Chest Hospital
Shanghai, China